|Bid||16.65 x 1200|
|Ask||16.66 x 1400|
|Day's range||16.57 - 16.95|
|52-week range||12.43 - 20.00|
|Beta (5Y monthly)||1.11|
|PE ratio (TTM)||20.56|
|Forward dividend & yield||0.85 (5.07%)|
|Ex-dividend date||29 Sep 2020|
|1y target est||22.88|
Takeda Pharmaceutical Company Limited (TOKYO:4502) (NYSE:TAK) ("Takeda") today announced that it has entered into an agreement to transfer the assets, marketing rights and, eventually, marketing authorization associated with a portfolio of select non-core products in Japan to Teijin Pharma Limited ("Teijin Pharma"), a Tokyo-based pharmaceutical company, for JPY 133.0 billion, subject to customary legal and regulatory closing conditions.
BioLife Plasma Services announces expansion of plasma donation centers into California.
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) announced today that the first subject was dosed in its Phase 1/2 immunogenicity and safety study of Novavax’ COVID-19 vaccine candidate (TAK-019) in Japan. Earlier this month, Takeda completed enrollment in the company’s Phase 1/2 immunogenicity and safety study of Moderna’s COVID-19 vaccine candidate (TAK-919) in Japan.